SFDA (Saudi)

SFDA (Saudi Food and Drug Authority, الهيئة العامة للغذاء والدواء) is the Kingdom of Saudi Arabia's central regulatory authority for foods, drugs, medical devices, cosmetics, pesticides + veterinary products. SFDA was established in 2003 + reorganised as an independent corporate-personality authority by Royal Decree A/30 of 2007, reporting directly to the Council of Ministers. SFDA's headquarters is in Riyadh, with regional offices + ports-of-entry inspection facilities across the Kingdom + approximately 2,500 staff.

The SFDA ecosystem includes:

• Drug Sector — therapeutic products, biologics, vaccines, controlled substances + pharmaceutical-establishment licensing.
• Food Sector — food safety, food establishment licensing, food import controls + food-borne disease surveillance.
• Medical Devices Sector — medical devices + IVDs registration, inspection + market surveillance.
• Cosmetics Executive Directorate — cosmetics registration + market surveillance.
• Veterinary Drugs Executive Directorate — veterinary medicines + biologicals.
• Pesticides Executive Directorate — pesticide registration + use.
• Drug Inspection Executive Directorate — GMP / GDP inspection programme for both domestic + foreign sites.
• Pharmacovigilance + Drug Safety Executive Directorate — National Pharmacovigilance + Drug Safety Center (NPC); operates the Saudi national pharmacovigilance database + integrates with WHO VigiBase.
• GHAD — SFDA's medical-device unique-identification + tracking system (UDI-equivalent + supply-chain tracking platform).
• SDR (Saudi Drug Registration) — SFDA's drug-registration portal.

Legal foundations are the Drug + Pharmaceutical Establishments Law (Royal Decree M/31, 1426H — 2005), the Medical Devices Law + Executive Regulations, the SFDA Establishing Decree A/30 (2007), the Food Law + Executive Regulations + a substantial body of SFDA Implementing Regulations + Board Decisions + technical Guidelines. SFDA also operationalises the Gulf Cooperation Council (GCC) Centralized Drug Registration procedure + GCC Centralized Device Registration procedure on behalf of the GCC Secretariat.

SFDA is a PIC/S Member since January 2021 (the first GCC regulator to achieve PIC/S Membership), an ICH Observer working toward Regulatory Membership, an IMDRF Affiliate Member + an active ICMRA participant. SFDA is the lead regulator for the GCC Centralized Drug Registration + GCC Centralized Device Registration procedures + holds bilateral MoUs with FDA, EMA, MHRA, Health Canada, TGA, PMDA + many others.

The Gulf Cooperation Council (GCC) Centralized Drug Registration procedure is a regional work-sharing pathway across the GCC member states (Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman + Yemen — Yemen membership suspended). SFDA leads the GCC Centralized procedure on behalf of the GCC Secretariat + the GCC Executive Board of Health Ministers.

• GCC Centralized Drug Registration — single submission to the GCC Executive Board with SFDA as default Rapporteur; rotating Co-Rapporteur from another GCC member; harmonised assessment + final marketing authorisation issued nationally by each member state.
• GCC Centralized Device Registration — analogous centralised pathway for medical devices; SFDA Medical Devices Sector lead.
• GCC Common Technical Document (GCC-CTD) — harmonised dossier format substantively aligned with ICH CTD with GCC-specific Module 1.
• GCC GMP framework — substantively aligned with PIC/S GMP + ICH Q7; SFDA + UAE Ministry of Health (now Emirates Drug Establishment) + Kuwait Ministry of Health are the principal GCC inspectorate members.
• GCC Drug Price List — harmonised pricing framework across GCC member states based on international reference pricing.
• GCC Drug Information System — shared GCC drug-information database.
• GCC Pharmacovigilance — emerging regional pharmacovigilance coordination + signal-detection cooperation.
• Mutual reliance for legacy national registrations — products with national MA in one GCC member can be relied upon by other GCC members through bilateral arrangements + GCC reliance framework.
• SFDA's leadership role — SFDA's PIC/S Membership + ICH Observer status + technical capability make it the de-facto lead for many GCC scientific + regulatory initiatives.

• Class I — Lowest risk; SFDA Class I notification with reduced data requirements.
• Class II.A — Low-moderate risk; substantively equivalent to EU MDR Class IIa.
• Class II.B — Moderate-high risk; substantively equivalent to EU MDR Class IIb.
• Class III — Highest risk; substantively equivalent to EU MDR Class III.
• IVD classification — Class A / B / C / D substantively aligned with IVDR principles.
• Reference-regulator basis — SFDA recognises CE marking under EU MDR / IVDR, FDA 510(k) / De Novo / PMA, Health Canada, TGA, PMDA + MHRA as evidence supporting Saudi registration.
• MDSAP recognition — SFDA accepts MDSAP audit reports as part of Saudi QMS evidence package.
• Saudi Authorized Representative (SAR) — foreign manufacturers must designate a Saudi-registered Authorized Representative who holds the establishment licence + handles regulatory interactions with SFDA + pharmacovigilance.
• GHAD (SFDA Unified Drug + Device Tracking System) — Saudi UDI + supply-chain tracking platform; mandatory for medical devices + drugs across importation, distribution + dispensing channels; implements GS1 standards + provides anti-counterfeiting + recall traceability.
• Establishment Licence — required for all Saudi-resident manufacturers, importers, wholesalers + Saudi Authorized Representatives.
• Clinical evaluation — Class II.B + III typically require Saudi clinical-investigation data or accepted reference-regulator clinical evidence; Class I + II.A may use literature + comparator data.
• Field Safety Corrective Action (FSCA) — SFDA FSCA + Field Safety Notice (FSN) framework substantively aligned with EU MDR + IMDRF.
• GCC Centralized Device Registration — alternative regional pathway with single submission across GCC member states.

• SFDA GMP — substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10; SFDA Implementing Regulations + Annexes parallel PIC/S Annexes.
• SFDA GDP — Saudi Good Distribution Practice for drugs + medical devices; substantively aligned with PIC/S GDP Guide.
• PIC/S Member since Jan 2021 — first GCC regulator to achieve PIC/S Membership; full reliance under PIC/S MoU.
• Reference Regulator network — SFDA recognises FDA, EMA, EU national, Health Canada, TGA, MHRA, Swissmedic, PMDA + others as reference regulators for both product authorisation reliance + GMP-evidence reliance.
• Overseas inspections — SFDA conducts overseas inspections of foreign sites supplying Saudi Arabia; risk-based programme prioritising new MA applications, biologics, sterile products + APIs; SFDA has substantially expanded its overseas-inspection capacity.
• Data integrity — SFDA Data Integrity Guideline substantively aligned with PIC/S PI 041 + MHRA + WHO + FDA; ALCOA+ + audit-trail + computerised-systems expectations.
• MDSAP — SFDA accepts MDSAP audit reports as Saudi device QMS evidence.
• GCC GMP harmonisation — SFDA leads GCC GMP framework alignment with PIC/S.
• Inspection findings + remediation — SFDA Inspection Reports + Warning Letters + manufacturing-licence suspension; published market actions on SFDA portal.
• Pharmaceutical Establishment Licensing — SFDA-issued licences for Saudi-resident manufacturers, importers, wholesalers + retail pharmacies; periodic renewal + inspection.

• National Pharmacovigilance + Drug Safety Center (NPC) — SFDA Executive Directorate operating the Saudi national pharmacovigilance database; E2B(R3)-compliant; integrated with WHO VigiBase via UMC Uppsala.
• ICSR reporting — Serious unexpected ADRs within 15 calendar days; non-serious in periodic reports + PSURs per ICH E2D + SFDA Pharmacovigilance Guideline.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle.
• Risk Management Plan (RMP) — required for new active substances + biosimilars + new significant indications; per ICH E2E + SFDA RMP guidance.
• Saudi Qualified Person for Pharmacovigilance (SQPPV) — local pharmacovigilance contact required for Saudi MAH; substantively aligned with EU QPPV role.
• Saudi Pharmacovigilance Master File — equivalent to EU PSMF for new MAs + on-request inspection availability.
• Medical device adverse-event reporting — SFDA Medical Devices Sector FSCA + FSN framework substantively aligned with EU MDR vigilance.
• Healthcare-professional + consumer reporting — SFDA online reporting via SFDA portal + dedicated NPC channels.
• Recall — SFDA-coordinated recall framework with Pharmaceutical Establishments + healthcare institutions + GHAD-traceability support.
• Drug Shortages — SFDA Drug Shortage Reporting System; MAHs required to report shortages of essential medicines.
• SFDA Safety Communications — SFDA Notices + Safety Alerts published on SFDA portal + distributed to healthcare professionals.

• PIC/S Member since Jan 2021 — first GCC regulator to achieve PIC/S Membership; full GMP reliance with all PIC/S members.
• ICH Observer working toward Regulatory Membership — SFDA progressively adopting ICH guidelines + participating in ICH Working Groups.
• IMDRF Affiliate Member — active on UDI, SaMD, AI / ML, QMS work products.
• ICMRA — active member contributing on pandemic preparedness, supply chain, regulatory innovation, generics.
• WHO collaboration — SFDA participates in WHO PQ Collaborative Registration Procedure for LMIC NRAs + progressing toward WHO Listed Authority status; Saudi NRA function progressing through WHO Global Benchmarking Tool maturity assessment.
• GCC leadership — SFDA leads the GCC Centralized Drug Registration + GCC Centralized Device Registration procedures + GCC GMP framework + GCC Pharmacovigilance coordination.
• Arab League + EMRO — SFDA participates in Arab Health Ministers Council pharmaceutical initiatives + WHO Eastern Mediterranean Regional Office (EMRO) coordination.
• Bilateral MoUs — SFDA holds MoUs with FDA, EMA national authorities, Health Canada, TGA, MHRA, PMDA, MFDS, NMPA, ANVISA + many others; tight cooperation on inspections + information exchange.
• AUDA-NEPAD AMRH — Saudi support for African Medicines Regulatory Harmonization + AUDA-NEPAD partnerships.
• Saudi Vision 2030 alignment — SFDA's expansion of regulatory capacity is a key element of Saudi Vision 2030 healthcare-system + life-sciences-industry development.

• Saudi Authorized Representative (SAR) not properly designated for therapeutic products or medical devices — application rejected at SDR intake.
• Pharmaceutical Establishment Licence not in place or scope mismatched — market placement blocked.
• GHAD enrolment incomplete — products without GHAD UDI / serialisation not permitted through Saudi supply chain.
• Arabic-language labelling + IFU non-compliant — Saudi labelling typically requires Arabic + English; specific SFDA-required content + warnings + SAR contact details.
• GCC Centralized vs SFDA National pathway confusion — applicants choosing national pathway when GCC Centralized would have been more efficient (or vice versa).
• Reference-regulator basis for Reliance Pathway not properly documented — applicants providing partial assessment rather than full Day-0 to Day-X assessment report.
• SDR eCTD submission errors — module structure non-compliance, missing Module 1 Saudi-specific elements.
• NPC pharmacovigilance reporting timelines missed — Saudi SQPPV enforcement.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data.
• Sterile / aseptic process gaps — SFDA inspectorate alignment with EU GMP Annex 1 (2022 revision) creates new expectations + frequent findings.
• MDSAP audit-report packaging gap — SFDA accepts MDSAP but requires the full audit report + non-conformity closures.
• GHAD UDI database gaps — UDI-DI mismatch with GHAD database, packaging-hierarchy errors, serialisation gaps.
• Saudi clinical-trial CTA + Saudi National Bioethics Committee coordination gap.
• Hajj + Umrah seasonal supply planning — drug + medical-device supply for the Hajj + Umrah seasons requires SFDA-specific planning + may trigger expedited importation requirements.
• PSUR not aligned with International Birth Date — Saudi PSUR cycle out of sync with EMA PSUR / FDA PADER submissions.

V5 Ultimate provides the operational infrastructure Saudi + foreign-supplier sites need for Drug + Pharmaceutical Establishments Law + Medical Devices Law + SFDA Implementing Regulations compliance + SFDA readiness.

• SFDA GMP control framework — PIC/S-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + SFDA Data Integrity Guideline alignment.
• Saudi Authorized Representative (SAR) + Pharmaceutical Establishment Licence workflow — SAR designation, establishment-licence scope management, foreign-manufacturer QMS-evidence packaging.
• SDR submission packaging — eCTD-aligned dossier structure with Saudi Module 1 specifics, reference-regulator assessment-report packaging for Reliance Pathway, GCC-CTD-aligned dossier for GCC Centralized procedures.
• GCC Centralized Drug Registration workflow — Rapporteur / Co-Rapporteur tracking, GCC-CTD Module 1 packaging, GCC Executive Board submission management, national-level final-MA tracking per member state.
• Reference-regulator bridging — FDA / EMA / Health Canada / TGA / MHRA / Swissmedic / PMDA assessment-report packaging for SFDA Reliance Pathway; Saudi-specific data overlay.
• Medical Device + IVD registration workflow — Class I / II.A / II.B / III + Class A-D IVD classification, MDSAP + ISO 13485 audit-report packaging, GCC Centralized Device Registration tracking.
• GHAD — UDI-DI assignment per GS1 standards + UDI-PI + serialisation lifecycle + GHAD database submission + supply-chain tracking from manufacturer to dispensing channel.
• Arabic + English labelling + IFU — bilingual artwork workflow with two-person review + e-signature; SFDA-required elements + warnings + storage conditions + SAR details + Hajj + Umrah seasonal packaging considerations.
• NPC pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR timeline, PSUR / RMP packaging, Saudi SQPPV workflow + Saudi PSMF.
• Medical device vigilance — FSCA + FSN reporting per SFDA framework + IMDRF alignment; GHAD-linked surveillance.
• GCC dual-market workflow — for companies operating across GCC member states, V5 surfaces GCC-harmonised dossier-element reuse alongside member-state-specific extensions.
• Hajj + Umrah supply planning — for companies supplying critical medicines + devices for Hajj + Umrah seasons, V5 surfaces SFDA expedited-importation + capacity-planning workflow.